There are currently 1255 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing
NCT06105801
Recruiting
This is a multi-center clinical trial evaluating the effect of transbronchial mediastinal cryobiopsy for its ability to improve the likelihood of obtaining tissue sufficient for molecular analysis. Patients in outpatient clinics or pre-operative holding areas planning to undergo a bronchoscopic biopsy of a suspected malignant lesion (peripheral or mediastinal) for initial diagnosis, staging, or tissue acquisition for molecular analysis will be considered for enrollment and consented. Patients wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Lung Cancer
Register for Updates
Barriers and Facilitators to OTC Hearing Aids Success
NCT06499805
Recruiting
Hearing aids can improve hearing, communication, and overall quality of life for people with hearing loss. However, not many people use hearing aids. A common reason is that hearing aids are expensive and hard to get. The traditional way to get hearing aids involves multiple visits to licensed audiologists for identifying hearing loss, customizing the aids, and ongoing maintenance. This traditional method is called the AUD pathway. Over-the-counter (OTC) hearing aids offer a different approach.... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
05/20/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Hearing Loss, Sensorineural, Presbycusis
Register for Updates
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987
Recruiting
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/20/2025
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer, Lung Cancer, Triple Negative Breast Cancer, Breast Neoplasms, Neuroendocrine Tumors, Neuroendocrine Carcinoma, RB1 Gene Mutation
Register for Updates
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
NCT03706833
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Centennial Medical Center, Nashville, Tennessee +2 locations
Conditions: Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Register for Updates
Cabozantinib for Patients With Recurrent or Progressive Meningioma
NCT05425004
Recruiting
A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Meningioma
Register for Updates
Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)
NCT05765175
Recruiting
RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and are candidates for additional CA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Tachycardia, Ventricular
Register for Updates
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222
Recruiting
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Register for Updates
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
NCT06664502
Recruiting
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4 weeks apart. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE201 will be assessed at increasing doses in branch retinal vein occlusion (BRVO) participants. Approximately 12 participants will be entered in this part of the s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Nashville, Tennessee, Nashville, Tennessee
Conditions: Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
Register for Updates
Parkinson's Foundation PD GENEration Genetic Registry
NCT04994015
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Parkinson's Disease
Register for Updates
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
NCT05296070
Recruiting
The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on the participant and the participant's condition.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Marginal Zone Lymphoma
Register for Updates
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
NCT04884815
Recruiting
The primary objectives of this study are to evaluate the safety of single IV doses of UX701 in patients with Wilson disease, to select the UX701 dose with the best benefit/risk profile based on the totality of safety and efficacy data and to evaluate the effect of UX701 on copper regulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Wilson Disease
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Tennessee Oncology, PLLC,2004 Hayes Street, Nashville, Tennessee +5 locations
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates